EA200900531A1 - Фармацевтические составы - Google Patents

Фармацевтические составы

Info

Publication number
EA200900531A1
EA200900531A1 EA200900531A EA200900531A EA200900531A1 EA 200900531 A1 EA200900531 A1 EA 200900531A1 EA 200900531 A EA200900531 A EA 200900531A EA 200900531 A EA200900531 A EA 200900531A EA 200900531 A1 EA200900531 A1 EA 200900531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
active substance
composition
acid salt
polymer matrix
Prior art date
Application number
EA200900531A
Other languages
English (en)
Russian (ru)
Inventor
Йи Гао
Р. Йю Тцучи
Деннис Й. Ли
Николь Нгуен
Хауилианг Ву
Original Assignee
Эббот Лаборейторис
Форнэр Лаборейторис Айерлэнд Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббот Лаборейторис, Форнэр Лаборейторис Айерлэнд Лтд. filed Critical Эббот Лаборейторис
Publication of EA200900531A1 publication Critical patent/EA200900531A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200900531A 2006-10-12 2007-10-12 Фармацевтические составы EA200900531A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12
PCT/US2007/081267 WO2008046052A1 (en) 2006-10-12 2007-10-12 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
EA200900531A1 true EA200900531A1 (ru) 2009-12-30

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900531A EA200900531A1 (ru) 2006-10-12 2007-10-12 Фармацевтические составы

Country Status (14)

Country Link
EP (1) EP2081563A1 (enExample)
JP (1) JP2010506855A (enExample)
KR (1) KR20090119959A (enExample)
CN (1) CN101677981A (enExample)
AU (1) AU2007307641A1 (enExample)
CA (1) CA2672686A1 (enExample)
CO (1) CO6160302A2 (enExample)
EA (1) EA200900531A1 (enExample)
EC (1) ECSP099251A (enExample)
IL (1) IL198160A0 (enExample)
MX (1) MX2009003815A (enExample)
SG (1) SG175570A1 (enExample)
WO (1) WO2008046052A1 (enExample)
ZA (1) ZA200902488B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2285357T3 (da) * 2008-05-30 2014-06-02 Ucb Pharma Sa Farmaceutisk sammensætning omfattende brivaracetam
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技(苏州)有限公司 二氟非诺贝特酸及其在药学上可接受的盐,以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1829541A1 (en) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP5114382B2 (ja) * 2005-04-08 2013-01-09 アボット・ラボラトリーズ フェノフィブリン酸および/またはそれの塩を含む経口医薬製剤

Also Published As

Publication number Publication date
SG175570A1 (en) 2011-11-28
WO2008046052A1 (en) 2008-04-17
CN101677981A (zh) 2010-03-24
KR20090119959A (ko) 2009-11-23
JP2010506855A (ja) 2010-03-04
MX2009003815A (es) 2009-09-07
CA2672686A1 (en) 2008-04-17
IL198160A0 (en) 2009-12-24
AU2007307641A1 (en) 2008-04-17
ECSP099251A (es) 2009-06-30
EP2081563A1 (en) 2009-07-29
ZA200902488B (en) 2010-10-27
CO6160302A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
PL2148703T3 (pl) Nowy środek umożliwiający wysalanie substancji czynnych w opatrunkach zawierających co najmniej jedną substancję tłuszczową
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CN115038465A (zh) 炎症反应性抗炎水凝胶
BR112013016772B8 (pt) compostos, uso do composto e composição farmacêutica
CY1113207T1 (el) Στερεη μορφη δοσολογιας που περιεχει αναστολεα αντλιας πρωτονιων και εναιωρημα που παρασκευαζεται απο αυτη
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
Liu et al. Biological glue from only lipoic acid for scarless wound healing by anti-inflammation and TGF-β regulation
CA3123813C (en) IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
EA200900531A1 (ru) Фармацевтические составы
WO2008149035A3 (fr) Nouveau principe actif dans la cicatrisation et son utilisation
ATE543507T1 (de) Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
TR201820076T4 (tr) İlaç kombinasyonlarının salımı.
EA201100287A1 (ru) Композиция ропинирола
TR201906158T4 (tr) Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar.
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
ITRM20050393A1 (it) Sistema di rilascio controllato di sostanze farmacologicamente attive, processo di preparazione e impieghi in campo medico.
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
EA201190050A1 (ru) Композиция кветиапина
ATE438385T1 (de) Pharmazeutische zusammensetzung
EA200701228A1 (ru) Стабильные композиции фенофибрата с эфирами жирных кислот